









Markets
/
Stocks
/
nasdaq-cdna
/

CareDx Inc

CDNA

19.470USD

+1.120+6.10%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.00BMarket Cap

14.43P/E TTM



CareDx Inc

19.470

+1.120+6.10%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CareDx Inc

Currency: USD Updated: 2026-02-06

Key Insights

CareDx Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.20.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CareDx Inc's Score

Industry at a Glance

Industry Ranking

9 / 392

Overall Ranking

82 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

CareDx Inc Highlights

StrengthsRisks

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 14.43, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 52.64M shares, increasing 0.08% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 2.17M shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

23.200

Target Price

+26.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of CareDx Inc is 9.34, ranking 6 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 100.06M, representing a year-over-year increase of 20.72%, while its net profit experienced a year-over-year increase of 122.61%.

Score

Industry at a Glance

Previous score

9.34

Change



Financials

9.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.75

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CareDx Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of CareDx Inc is 6.45, ranking 277 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 14.43, which is 74.44% below the recent high of 25.18 and 184.92% above the recent low of -12.26.

Score

Industry at a Glance

Previous score

6.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of CareDx Inc is 7.25, ranking 304 out of 392 in the Biotechnology & Medical Research industry. The average price target is 24.50, with a high of 28.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

7.25

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

23.200

Target Price

+26.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

CareDx Inc

CDNA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of CareDx Inc is 8.81, ranking 55 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 21.66 and the support level at 17.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.10

Change

1.71

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.482

Neutral

RSI(14)

48.066

Neutral

STOCH(KDJ)(9,3,3)

26.700

Neutral

ATR(14)

1.017

High Vlolatility

CCI(14)

-135.694

Sell

Williams %R

62.096

Sell

TRIX(12,20)

0.167

Sell

StochRSI(14)

51.619

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

19.560

Sell

MA10

20.099

Sell

MA20

20.113

Sell

MA50

19.459

Buy

MA100

17.309

Buy

MA200

16.559

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CareDx Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 115.22%, representing a quarter-over-quarter decrease of 0.64%. The largest institutional shareholder is The Vanguard, holding a total of 3.42M shares, representing 6.64% of shares outstanding, with 23.30% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

4.12M

+1.33%

The Vanguard Group, Inc.

Star Investors

3.74M

-23.69%

Baron Capital Management, Inc.

Star Investors

3.16M

+29.54%

State Street Investment Management (US)

2.57M

+17.72%

Ophir Asset Management Pty Ltd

2.20M

+16.11%

Deerfield Management Company, L.P.

2.19M

Braidwell LP

2.18M

ARK Investment Management LLC

Star Investors

2.17M

+3.36%

Gagnon Securities LLC

1.73M

-18.96%

Amova Asset Management Co., Ltd.

1.74M

+40.68%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CareDx Inc is 5.82, ranking 37 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.